Compare BLKB & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLKB | IRON |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | 2004 | 2020 |
| Metric | BLKB | IRON |
|---|---|---|
| Price | $39.15 | $71.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $60.00 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 543.5K | 324.5K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.32 | N/A |
| EPS | ★ 2.37 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.26 | N/A |
| Revenue Next Year | $4.25 | $283.52 |
| P/E Ratio | $16.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.95 | $40.00 |
| 52 Week High | $74.86 | $99.50 |
| Indicator | BLKB | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 45.85 | 64.04 |
| Support Level | $33.95 | $70.29 |
| Resistance Level | $40.60 | $82.70 |
| Average True Range (ATR) | 1.81 | 2.56 |
| MACD | 0.57 | 0.89 |
| Stochastic Oscillator | 76.99 | 89.92 |
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.